ERBB2 and neoplasm: In addition, downregulation of the tumor suppressor miR-4319, which suppresses HER2 expression, was associated with poor chemotherapy response in prostate cancer patients and induced miR-4319 expression sensitized prostate cancer cells to estramustine treatment[60].